PriceTargets.com logo

Opsens - OPS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: C$2.90
  • Forecasted Upside: ∞
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00 As of 12/14/2023 12:59 AM ET
+0 (0.00%)

This chart shows the closing price for OPS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Opsens Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPS

Analyst Price Target is C$2.90
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Opsens in the last 3 months. The average price target is C$2.90, with a high forecast of C$2.90 and a low forecast of C$2.90. The average price target represents a ∞ upside from the last price of C$0.00.

This chart shows the closing price for OPS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Opsens. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/11/2023Raymond JamesDowngradeOutperform ➝ Market PerformC$3.50 ➝ C$2.90
4/10/2023Royal Bank of CanadaLower TargetOutperformC$4.00 ➝ C$3.50
3/28/2023Bloom BurtonReiterated RatingBuy
12/23/2022Raymond JamesLower TargetOutperformC$5.00 ➝ C$3.50
11/23/2022Raymond JamesDowngradeStrong-Buy ➝ OutperformC$6.00 ➝ C$5.00
9/29/2022Stifel NicolausBoost TargetC$3.35 ➝ C$3.75
9/8/2022Raymond JamesReiterated RatingBuyC$6.00
4/27/2022Raymond JamesSet TargetStrong-BuyC$6.00
4/14/2022Raymond JamesSet TargetStrong-BuyC$6.00
4/13/2022Stifel NicolausInitiated CoverageBuyC$3.35
2/22/2022Raymond JamesBoost TargetStrong-BuyC$6.00
2/22/2022Raymond JamesSet TargetStrong-BuyC$6.00
2/2/2022Raymond JamesSet TargetStrong-BuyC$6.00
2/2/2022Raymond JamesReiterated RatingStrong-BuyC$6.00
1/12/2022Raymond JamesSet TargetStrong-BuyC$6.00
1/12/2022Raymond JamesReiterated RatingStrong-BuyC$6.00
1/4/2022Royal Bank of CanadaBoost TargetOutperformC$4.00
12/31/2021Royal Bank of CanadaBoost TargetOutperformC$3.50 ➝ C$4.00
12/14/2021Raymond JamesSet TargetStrong-BuyC$6.00
11/24/2021Raymond JamesUpgradeOutperform ➝ Strong-BuyC$6.00
11/18/2021Raymond JamesSet TargetOutperformC$6.00
11/2/2021Raymond JamesSet TargetOutperformC$6.00
10/14/2021Raymond JamesSet TargetOutperformC$6.00
10/14/2021Raymond JamesReiterated RatingOutperformC$6.00
9/21/2021Raymond JamesBoost TargetOutperformC$6.00
9/21/2021Royal Bank of CanadaReiterated RatingBuyC$3.50
7/14/2021Raymond JamesReiterated RatingOutperformC$2.75
7/14/2021Raymond JamesSet TargetOutperformC$2.75
7/14/2021Royal Bank of CanadaReiterated RatingOutperformC$3.50
7/14/2021M PartnersSet TargetC$2.25
7/13/2021M PartnersReiterated RatingBuy
6/11/2021Raymond JamesSet TargetOutperformC$2.75
6/11/2021Raymond JamesReiterated RatingOutperformC$2.75
4/27/2021Royal Bank of CanadaBoost TargetOutperformC$2.25 ➝ C$3.50
4/15/2021Raymond JamesReiterated RatingOutperformC$2.75
4/15/2021Royal Bank of CanadaBoost TargetOutperformC$2.00 ➝ C$2.25
4/15/2021Raymond JamesSet TargetOutperformC$2.75
4/8/2021Raymond JamesBoost TargetOutperformC$2.50 ➝ C$2.75
4/8/2021Royal Bank of CanadaReiterated RatingOutperformC$2.00
2/1/2021Raymond JamesReiterated RatingOutperformC$2.50
2/1/2021Raymond JamesSet TargetOutperformC$2.50
1/15/2021Royal Bank of CanadaReiterated RatingOutperformC$2.00
1/14/2021Royal Bank of CanadaBoost TargetOutperformC$1.50 ➝ C$2.00
11/23/2020Royal Bank of CanadaBoost TargetOutperformC$1.25 ➝ C$1.50
7/16/2020Royal Bank of CanadaLower TargetOutperformC$1.50 ➝ C$1.25
7/9/2020M PartnersReiterated RatingBuy
4/13/2020Royal Bank of CanadaLower TargetOutperformC$2.00 ➝ C$1.50
(Data available from 4/26/2019 forward)

News Sentiment Rating

1.57 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Opsens logo
Opsens Inc. develops, manufactures, installs, and sells fiber optic sensors for cardiovascular interventions. The company operates in two segments, Medical and Industrial. The company provides advanced optical-based pressure guidewire (OptoWire), a guidewire used in the transcatheter aortic valve replacement procedure; and a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated in other medical devices. It also develops, manufactures, and markets medical products; and offers OPP-GD fiber optic differential pressure sensors and the OEC fiber optic extensometer sensors. The company serves life sciences, energy, defense and aerospace, geotechnical, civil engineering, scientific laboratory, and various other markets. The company sells its products through a network of distributors and direct sales force in the United States, Japan, Canada, and internationally. Opsens Inc. was formerly known as Capital DCB inc. and changed its name to OpSens Inc. in October 2006. The company was founded in 2003 and is headquartered in Québec, Canada. As of December 12, 2023, Opsens Inc. operates as a subsidiary of Haemonetics Corporation.
Read More

Today's Range

Now: N/A

50 Day Range

MA: C$2.89
Low: C$2.85
High: C$2.90

52 Week Range

Now: N/A

Volume

49,783 shs

Average Volume

112,402 shs

Market Capitalization

C$335.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Opsens?

The following Wall Street sell-side analysts have issued research reports on Opsens in the last twelve months: Raymond James.
View the latest analyst ratings for OPS.

What is the current price target for Opsens?

1 Wall Street analysts have set twelve-month price targets for Opsens in the last year. Their average twelve-month price target is C$2.90. Raymond James has the highest price target set, predicting OPS will reach C$2.90 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of C$2.90 for Opsens in the next year.
View the latest price targets for OPS.

What is the current consensus analyst rating for Opsens?

Opsens currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OPS, but not buy more shares or sell existing shares.
View the latest ratings for OPS.

What other companies compete with Opsens?

Other companies that are similar to Opsens include CRH Medical, Zentek, Dialogue Health Technologies, Fennec Pharmaceuticals and ProMetic Life Sciences. Learn More about companies similar to Opsens.

How do I contact Opsens' investor relations team?

Opsens' physical mailing address is 750 Boulevard du Parc Technologique, Québec, QC G1P 4S3, Canada, . The company's listed phone number is 418-781-0333. The official website for Opsens is opsens.com. Learn More about contacing Opsens investor relations.